Head to Head Survey: Delcath Systems (NASDAQ:DCTH) and Micron Solutions (OTCMKTS:MICR)

Delcath Systems (NASDAQ:DCTH) and Micron Solutions (OTCMKTS:MICR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Volatility & Risk

Delcath Systems has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Micron Solutions has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Delcath Systems and Micron Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1	0	5	0	2.67
Micron Solutions	0	0	0	0	0.00

Delcath Systems currently has a consensus target price of $22.40, indicating a potential upside of 139.06%. Given Delcath Systems’ stronger consensus rating and higher probable upside, analysts clearly believe Delcath Systems is more favorable than Micron Solutions.

Earnings & Valuation

This table compares Delcath Systems and Micron Solutions”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$37.21 million	8.89	-$26.39 million	$0.01	937.00
Micron Solutions	N/A	N/A	N/A	($0.36)	0.00

Micron Solutions has lower revenue, but higher earnings than Delcath Systems. Micron Solutions is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

61.1% of Delcath Systems shares are held by institutional investors. 17.4% of Delcath Systems shares are held by insiders. Comparatively, 26.1% of Micron Solutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Delcath Systems and Micron Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delcath Systems	1.50%	7.02%	6.39%
Micron Solutions	N/A	N/A	N/A

Summary

Delcath Systems beats Micron Solutions on 11 of the 12 factors compared between the two stocks.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

About Micron Solutions

Micron Solutions, Inc. operates as a contract manufacturer for the medical device, defense, and life sciences markets. It offers precision machining, thermoplastic injection molding, mold making products; sensors; orthopedic implants and devices; and diagnostic test kits. The company provides solutions for medical, orthopedics, consumer, and automotive industries. Micron Solutions, Inc. was founded in 1978 and is based in Fitchburg, Massachusetts.